首页> 美国卫生研究院文献>Croatian Medical Journal >Conflicts of interest in biomedical publications: considerations for authors peer reviewers and editors
【2h】

Conflicts of interest in biomedical publications: considerations for authors peer reviewers and editors

机译:生物医学出版物中的利益冲突:作者同行审稿人和编辑的注意事项

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article overviews evidence on common instances of conflict of interest (COI) in research publications from general and specialized fields of biomedicine. Financial COIs are viewed as the most powerful source of bias, which may even distort citation outcomes of sponsored publications. The urge to boost journal citation indicators by stakeholders of science communication is viewed as a new secondary interest, which may compromize the interaction between authors, peer reviewers, and editors. Comprehensive policies on disclosure of financial and non-financial COIs in scholarly journals are presented as proxies of their indexing in evidence-based databases, and examples of successful medical journals are discussed in detail. Reports on clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines may be unduly influenced by author-pharmaceutical industry relations, but these publications do not always contain explicit disclosures to allow the readers to judge the reliability of the published conclusions and practice-changing recommendations. The article emphasizes the importance of adhering to the guidance on COI from learned associations such as the International Committee of Medical Journal Editors (ICMJE). It also considers joint efforts of authors, peer reviewers, and editors as a foundation for appropriately defining and disclosing potential COIs.
机译:本文概述了生物医学的一般和专门领域的研究出版物中有关利益冲突(COI)常见情况的证据。财务COI被视为最有力的偏见来源,甚至可能扭曲赞助出版物的引文结果。科学传播的利益相关者提高期刊引文指标的冲动被视为一种新的次要利益,这可能会损害作者,同行审稿人和编辑之间的互动。提出了关于在学术期刊中公开金融和非金融COI的综合政策,作为它们在基于证据的数据库中建立索引的代理,并详细讨论了成功医学期刊的示例。关于临床试验,系统评价,荟萃分析和临床实践指南的报告可能会受到作者与制药行业关系的过分影响,但是这些出版物并不总是包含明确的披露内容,以使读者能够判断已发表结论和实践的可靠性。不断变化的建议。本文强调必须遵守国际医学期刊编辑委员会(ICMJE)等学术协会对COI的指导。它还将作者,同行审稿人和编辑的共同努力作为适当定义和披露潜在COI的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号